Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer.
Biomarkers, Tumor
/ genetics
Case-Control Studies
Early Detection of Cancer
Female
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Gene Regulatory Networks
Humans
Intracellular Signaling Peptides and Proteins
/ genetics
Kaplan-Meier Estimate
Male
Nuclear Proteins
/ genetics
Pancreatic Neoplasms
/ diagnosis
Prognosis
ROC Curve
Survival Analysis
Up-Regulation
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
21
10
2018
accepted:
10
01
2019
entrez:
30
1
2019
pubmed:
30
1
2019
medline:
28
10
2019
Statut:
epublish
Résumé
FAM64A, a marker of cell proliferation, has been investigated as a potential biomarker in several cancers. In the present study, we examined the value of FAM64A expression in the diagnosis and prognosis of pancreatic cancer through bioinformatics analysis of data obtained from The Cancer Genome Atlas (TCGA) database. The diagnostic value of FAM64A expression in pancreatic cancer tissue was deteremined through receiver operating characteristic (ROC) curve analysis, and based on the obtained cut-off value, patients were divided into two groups (high FAM64A expression and low FAM64A expression). Chi-square and Fisher exact tests were applied to identify associations between FAM64A expression and clinical features. Moreover, the effect of FAM64A expression in the survival of pancreatic cancer patients was observed by Kaplan-Meier and Cox analyses. Gene set enrichment analysis (GSEA) was performed using the TCGA dataset. Our results showed that high FAM64A expression in pancreatic cancer was associated with survival status, overall survival (OS), and recurrence. The area under the ROC curve was 0.736, which indicated modest diagnostic value. Patients with higher FAM64A expression had significantly shorter OS and recurrence-free survival (RFS) times. Multivariate survival analysis demonstrated that high FAM64A expression was an independent risk factor for OS and RFS. GSEA identified mitotic spindles, myc targets, MTORC1 signaling, G2M checkpoint, E2F targets, DNA repair, glycolysis and unfolded protein response as differentially enriched with the high FAM64A expression phenotype. In conclusion, high FAM64A mRNA expression is an independent risk factor for poor prognosis in pancreatic cancer.
Identifiants
pubmed: 30695070
doi: 10.1371/journal.pone.0211291
pii: PONE-D-18-30380
pmc: PMC6351057
doi:
Substances chimiques
Biomarkers, Tumor
0
Intracellular Signaling Peptides and Proteins
0
Nuclear Proteins
0
PIMREG protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0211291Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 2016 Jul 2;388(10039):73-85
pubmed: 26830752
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33
pubmed: 27322403
World J Gastroenterol. 2018 May 21;24(19):2047-2060
pubmed: 29785074
RNA Biol. 2012 Jun;9(6):703-19
pubmed: 22664915
Gastroenterology. 2013 Jun;144(6):1252-61
pubmed: 23622135
Cancer Sci. 2018 Sep;109(9):2919-2936
pubmed: 29968393
Mol Oncol. 2008 Dec;2(4):356-67
pubmed: 19383357
Biochim Biophys Acta. 2013 May;1833(5):1269-79
pubmed: 23419774
Sci Rep. 2017 Jun 30;7(1):4486
pubmed: 28667270
Oncotarget. 2017 Jun 20;8(25):41334-41347
pubmed: 28489584
Nucleic Acids Res. 2014 Aug;42(14):e113
pubmed: 25030904
Oncotarget. 2016 Oct 18;7(42):68385-68396
pubmed: 27588395
Oncogene. 2006 Jul 6;25(29):4099-109
pubmed: 16491119
BMC Bioinformatics. 2011 Mar 17;12:77
pubmed: 21414208
Nat Genet. 2003 Jul;34(3):267-73
pubmed: 12808457
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Int J Oncol. 2014 Jun;44(6):2025-33
pubmed: 24676531